Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer A

11-11-2013 Business Wire HealthComments (0)


Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced today final 18-month survival data from Lm-LLO-E7-15, a randomized Phase 2 study evaluating the safety and efficacy of ADXS-HPV (1x109 cfu) (ADXS11-001) with and without cisplatin (40 mg/m2, weekly x5) in 110 patients with recurrent cervical cancer in two treatment arms of 55 patients each. The primary endpoint of the study is overall survival. These da

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top